These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 33564291)

  • 1. Successful Treatment of Advanced Thymic Carcinoma with Carboplatin plus
    Araya T; Kita T; Matsuoka H; Sakai T; Kimura H; Kasahara K
    Case Rep Oncol; 2020; 13(3):1506-1512. PubMed ID: 33564291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-Line Treatment with Carboplatin plus
    Funaishi K; Yamasaki M; Saito N; Daido W; Ishiyama S; Deguchi N; Taniwaki M; Ohashi N
    Case Rep Oncol; 2017; 10(2):571-576. PubMed ID: 28868014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. nab-Paclitaxel in Combination with Carboplatin for a Previously Treated Thymic Carcinoma.
    Makimoto G; Fujiwara K; Watanabe H; Kameyama N; Matsushita M; Rai K; Sato K; Yonei T; Sato T; Shibayama T
    Case Rep Oncol; 2014 Jan; 7(1):14-7. PubMed ID: 24575009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response to chemotherapy with carboplatin plus albumin-bound paclitaxel in a patient with lymphoepithelioma-like thymic carcinoma: A case report.
    Shima H; Ozasa H; Tsuji T; Ajimizu H; Nomizo T; Yagi Y; Sakamori Y; Nagai H; Minamiguchi S; Kim YH; Mishima M
    Mol Clin Oncol; 2016 May; 4(5):715-718. PubMed ID: 27123268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination carboplatin and nab-paclitaxel as a first-line treatment for advanced thymic carcinoma.
    Manaka H; Igawa S; Yamamoto M; Oguri A; Manabe H; Kasajima M; Kusuhara S; Hosotani S; Nakahara Y; Sato T; Fukui T; Hisashi M; Sasaki J; Naoki K
    Invest New Drugs; 2023 Feb; 41(1):115-121. PubMed ID: 36633784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A case of thymic cancer effectively treated by weekly paclitaxel combined with carboplatin].
    Kondo R; Watanabe S; Ishikawa D; Tanaka T; Ohshima Y; Asakawa K; Sakagami T; Okajima M; Miura S; Hayashi Y; Tanaka J; Kagamu H; Yoshizawa H; Narita I
    Gan To Kagaku Ryoho; 2014 Dec; 41(13):2607-9. PubMed ID: 25596057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Good Response of Advanced Thymic Carcinoma with Low PD-L1 Expression to Chemotherapy plus Pembrolizumab as First-Line Therapy and to Pembrolizumab as Maintenance Therapy: A Case Report.
    Nishii Y; Furuhashi K; Ito K; Sakaguchi T; Suzuki Y; Fujiwara K; Yasuma T; Kobayashi T; D'Alessandro-Gabazza CN; Gabazza EC; Taguchi O; Hataji O
    Pharmaceuticals (Basel); 2022 Jul; 15(7):. PubMed ID: 35890187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Safety and Efficacy of Treatment with Nab-paclitaxel and Carboplatin for Patients with Advanced Squamous Non-small Cell Lung Cancer Concurrent with Idiopathic Interstitial Pneumonias.
    Fujita T; Hiroishi T; Shikano K; Yanagisawa A; Hayama N; Amano H; Nakamura M; Hirano S; Tabeta H; Nakamura S
    Intern Med; 2018 Jul; 57(13):1827-1832. PubMed ID: 29434143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switch maintenance therapy with S-1 after induction therapy with carboplatin and nanoparticle albumin-bound paclitaxel in advanced lung squamous cell carcinoma.
    Akiyama N; Karayama M; Inui N; Yasui H; Hozumi H; Suzuki Y; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Inami N; Matsuura S; Kaida Y; Uto T; Matsui T; Asada K; Matsuda H; Fujii M; Toyoshima M; Suda T
    Invest New Drugs; 2019 Jun; 37(3):531-537. PubMed ID: 30790149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful chemotherapy with carboplatin and nab-paclitaxel for thymic large cell neuroendocrine carcinoma: A case report.
    Igawa S; Yanagisawa N; Niwa H; Ishihara M; Hiyoshi Y; Otani S; Katono K; Sasaki J; Satoh Y; Masuda N
    Oncol Lett; 2015 Dec; 10(6):3519-3522. PubMed ID: 26788161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy of carboplatin plus nanoparticle albumin-bound paclitaxel after cisplatin plus pemetrexed in non-squamous non-small-cell lung cancer patients.
    Tanaka M; Hattori Y; Ishii T; Tohnai R; Itoh S; Kawa Y; Kono Y; Urata Y; Satouchi M
    Respir Investig; 2020 Jul; 58(4):269-274. PubMed ID: 32111518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of nanoparticle albumin-bound paclitaxel in combination with carboplatin as a late-phase chemotherapy for recurrent and advanced non-small-cell lung cancer: A multi-center study of the Fukushima lung cancer association group of surgeons.
    Higuchi M; Takagi H; Owada Y; Inoue T; Watanabe Y; Yamaura T; Fukuhara M; Muto S; Okabe N; Matsumura Y; Hasegawa T; Yonechi A; Osugi J; Hoshino M; Shio Y; Fujiu K; Kanno R; Ohishi A; Suzuki H; Gotoh M
    Oncol Lett; 2017 Jun; 13(6):4315-4321. PubMed ID: 28599432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of nab-paclitaxel and carboplatin chemotherapy plus necitumumab in the first-line treatment of patients with stage IV squamous non-small cell lung cancer.
    Villaruz LC; Cobo M; Syrigos K; Mavroudis D; Zhang W; Kim JS; Socinski MA
    Lung Cancer; 2019 Oct; 136():52-56. PubMed ID: 31445354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strong and Sustained Response to Treatment with Carboplatin plus Nab-Paclitaxel in a Patient with Metastatic, Triple-Negative, BRCA1-Positive Breast Cancer.
    Shakir AR
    Case Rep Oncol; 2014 Jan; 7(1):252-9. PubMed ID: 24847251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A dose finding study of weekly and every-3-week nab-Paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small cell lung cancer.
    Socinski MA; Manikhas GM; Stroyakovsky DL; Makhson AN; Cheporov SV; Orlov SV; Yablonsky PK; Bhar P; Iglesias J
    J Thorac Oncol; 2010 Jun; 5(6):852-61. PubMed ID: 20521351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of weekly nab-paclitaxel and carboplatin treatment with or without trastuzumab as nonanthracycline neoadjuvant chemotherapy for locally advanced breast cancer.
    Huang L; Chen S; Yao L; Liu G; Wu J; Shao Z
    Int J Nanomedicine; 2015; 10():1969-75. PubMed ID: 25792830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A Case of Squamous Cell Lung Cancer in an Elderly Patient with Low PD-L1 Expression Effectively Treated with Nab-Paclitaxel(Nab-PTX)plus Carboplatin (CBDCA)plus Pembrolizumab for a Recurrence after Operation].
    Sakaguchi K; Kosaka M; Yamazaki Y
    Gan To Kagaku Ryoho; 2020 May; 47(5):819-821. PubMed ID: 32408327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of nanoparticle albumin-bound paclitaxel plus carboplatin in non-small lung cancer patients with malignant pleural effusion.
    Koyama N; Watanabe Y; Iwai Y; Miwa C; Nagai Y; Aoshiba K; Nakamura H
    Neoplasma; 2018; 65(1):132-139. PubMed ID: 29322797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer.
    Reynolds C; Barrera D; Jotte R; Spira AI; Weissman C; Boehm KA; Pritchard S; Asmar L
    J Thorac Oncol; 2009 Dec; 4(12):1537-43. PubMed ID: 19887966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nab-paclitaxel maintenance therapy following carboplatin + nab-paclitaxel combination therapy in chemotherapy naïve patients with advanced non-small cell lung cancer: multicenter, open-label, single-arm phase II trial.
    Nakao A; Uchino J; Igata F; On R; Ikeda T; Yatsugi H; Hirano R; Sasaki T; Tanimura K; Imabayashi T; Tamiya N; Kaneko Y; Yamada T; Nagata N; Watanabe K; Kishimoto J; Takayama K; Fujita M
    Invest New Drugs; 2018 Oct; 36(5):903-910. PubMed ID: 29846848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.